Tags: Drug.

AZD5423 is a phase II drug by AstraZeneca disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.

AZD5423_structure.svg
IUPAC name
222-Trifluoro-N-[(1R2S)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy-1-(3-methoxyphenyl)-2-propanyl]acetamide

Loading...

This page contains content from the copyrighted Wikipedia article "AZD5423"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.